LEGN legendbiotech.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Geopolitical risks and patent disputes in foreign markets are putting pressure on Legend Biotech (LEGN). The EV/EBITDA multiple, accounting for total debt, reflects the volatility in the perception of these threats, where the 0.00 level indicates the status of the parameter. Strategic alliances with pharma behemoths are stabilizing the situation, while the rapid sales growth of Carvykti amid the expansion of indications provides a powerful impulse for capitalization.

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit before taxes and amortization, allowing for an objective assessment of asset efficiency regardless of the financing structure. By analyzing the historical EV/EBITDA chart for Legend Biotech (LEGN), an investor can correlate the market value of Legend Biotech (LEGN) with the costs of scaling laboratories and the pace of cell therapy commercialization, identifying whether the asset is overbought against sales expectations.